Research programme: DGAT-1 inhibitors - Pfizer
Alternative Names: BAY-744113; PF-0441560Latest Information Update: 03 Aug 2009
At a glance
- Originator Bayer
- Developer Pfizer
- Class Antihyperlipidaemics; Obesity therapies
- Mechanism of Action Diacylglycerol O-acyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Obesity; Type 2 diabetes mellitus
Most Recent Events
- 03 Aug 2009 Discontinued - Preclinical for Type-2 diabetes mellitus in USA (unspecified route)
- 07 Nov 2008 Pfizer exits research activities in the area of obesity
- 30 Sep 2008 Discontinued - Preclinical for Obesity in USA (unspecified route)